NAIIS Presentation From ACIP to Immunized Arms

May 2025

Ochsner Health

Ochsner Health & Ochsner Health Network



- Not-for-Profit Integrated Healthcare System & Accountable Care Organization (ACO)
- · Located in the Gulf South
- One of the top 3 ACOs in the country by Quality Measures
- 47 hospitals and more than 300 health and urgent care centers
- 16 Retail and 2 Specialty Pharmacies
- 38,000 employees and over 4,600 employed and affiliated physicians in over 90 medical specialties and subspecialties
- 2.4M patient visits per year
- 70% of Primary Care visits in Value Based Contract arrangement
- #1 Employee spend= Prevention and Wellness

Introductions

- Employer (38,000 \$ for \$ risk)
- Accountable Care Organization (ACO)
 - Function as Payer
 - Value Based Care arrangements
 - CMS Payment Models
 - Shared Savings Contracts
 - MSSP arrangements
- Healthcare Provider (Ochsner Health)
 - · Clinical and Operational care delivery
 - · Value based vs. Fee for Service reimbursement
 - Acute Care, ER, Urgent Care, Specialist Care, Primary Care, Digital Medicine, Retail pharmacy...



2

Cowboys and Pit Crews

- Atul Gawande
 - •May 26th, 2011



- The problems of making health care work are large. The complexities are overwhelming governments, economies, and societies around the world.
- We have every indication, however, that where people in medicine combine their talents and efforts to design organized service to patients and local communities, extraordinary change can result.

Design Principles & Mission



"Inspiring healthier lives and stronger communities."

Humor as an antidote to stress and anxiety



Vaccine P&T Subcommittee Chair Feb. 2020

"Transactions don't heal people. Relationships do."

Product Review

- Comparable products?
- Place in therapy? Population served?
- · Efficacy and Safety? Benefit vs. Risk?
- Recommendation or Shared Clinical Decision?
- Coverage and reimbursement? Part B vs. Part D?
- · Compile and analyze all above information
- Contract pricing (GPO)?
- · Vaccine preventable disease risk & cost?
- Storage, handling, look alike/Sound alike?
- Consensus guidelines from Specialists?
- Operational Complexity? Documentation?

- Manufacturer clinical trial application (BLA)
- FDA product approval
- ACIP product review
- CDC approval and signatures
- Finalized MMWR
- Insurer P&T review
 - · Coverage & reimbursement
- Provider P&T review
 - EMR & IS Support (Health Maintenance)
 - · Financial implications
 - Operational considerations & Documentation (Make it easier to do the right thing)

Coverage and Site of Administration

- · Part B (Medical benefit)
 - Influenza
 - Pneumococcal

Pediatric patients (under 7 years)

Medicare patients

- Hepatitis B
- · Vaccines to treat an injury/disease
- Part D (Pharmacy benefit)
 - Shingles
 - RSV
 - Tdap Booster
 - Measles



Valuing RSV Prevention (2023)

Vaccine Efficacy:

- GSK LRTD VE Sever: 94.1%, ARI VE 71.7%.
- Pfizer LRTI VE: 82.6%, ARI VE: 62.1%.

Vaccine Cost:

- GSK Arexvy: \$300 Pfizer Abrysvo: \$300

- Enhanced Influenza historic use of ~50K doses
- Expect 30,000 patients would wish to become immunized.
- Expected Reimbursement: \$330
- 30,000 patients
- Plan Cost= 30,000*\$330 = \$9.9M
- Drug cost: 30k x \$300 = \$9M
- Operational income = \$0.9M
- Prevent 600 hospitalizations

<u>Nirsevimab</u>

- Drug Cost
- ~8,000 infants
- Total Preventative Cost RSV: patients * cost
- Cost per Hospitalization: \$15,000.00 per hospitalization

Break Even: Prevention of X# hospitalizations

Nirsevimab in All Infants Could Prevent 500,000 Medical Interventions due to RSV in the US Annually



